Drug news
Byetta is FDA approved for use with Insulin Glargine in Type 2 Diabetes
The FDA has approved a new use for Byetta (exenatide) injection from Amylin/Eli Lilly. Byetta is now approved as an add-on therapy to insulin glargine, with or without metformin and/or a thiazolidinedione (TZD), in conjunction with diet and exercise for adults with Type 2 Diabetes who are not achieving adequate glycemic control on insulin glargine alone.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.